Skip to content
🌐 Global🇮🇳 India📍 Asia-Pacific📍 Bihar📍 Delhi-NCR📍 East India📍 Europe📍 Gujarat📍 Karnataka📍 Kerala📍 Madhya Pradesh📍 Maharashtra📍 Middle East📍 North India📍 Northeast India📍 Punjab📍 Rajasthan📍 South India📍 Tamil Nadu📍 Telangana📍 United Kingdom📍 United States📍 Uttar Pradesh📍 West Bengal📍 West India
LIVE
Medium is launching a new note-taking app called TK◆Watch Live: Mamdani announcing new NYC winter storm initiative, $25 million Code Blue investment - CBS News◆Ancient underwater canyons reveal clues to the world's oldest animal life◆Russia Targets Ukraine's Power Grid Ahead of Abu Dhabi Peace Talks◆California Needs Clean Energy Electricians. This Oakland Center Is Training Them - KQED◆PM Modi, Zelensky Discuss Bilateral Ties, Peace Efforts In Russia War◆SUCC seeks action against teachers skipping biometric punching at Sanskrit varsity◆Cardiologists seek review of DGHS order banning re-use of single-use medical devices to reduce angioplasty costs◆Medium is launching a new note-taking app called TK◆Watch Live: Mamdani announcing new NYC winter storm initiative, $25 million Code Blue investment - CBS News◆Ancient underwater canyons reveal clues to the world's oldest animal life◆Russia Targets Ukraine's Power Grid Ahead of Abu Dhabi Peace Talks◆California Needs Clean Energy Electricians. This Oakland Center Is Training Them - KQED◆PM Modi, Zelensky Discuss Bilateral Ties, Peace Efforts In Russia War◆SUCC seeks action against teachers skipping biometric punching at Sanskrit varsity◆Cardiologists seek review of DGHS order banning re-use of single-use medical devices to reduce angioplasty costs◆
Home / Global Markets
Global Markets

A failed trial for a heart drug casts shadow over rivals developing similar therapies

The full data from the closely watched clinical trial showed that the drug had no cardiovascular benefit even though it reduced Lp(a) levels.

MarketWatchNovember 9, 20261 min read
Share this story
A failed trial for a heart drug casts shadow over rivals developing similar therapies

The full data from the closely watched clinical trial showed that the drug had no cardiovascular benefit even though it reduced Lp(a) levels.

marketsworld
📡 Verified Wire Agency Verified Resource & Provenance
Original Resource
MarketWatch
Read Wire Dispatch → Share on 𝕏
✉
The Next Brief
Get the day's most important stories in one email
AI-curated morning digest. No noise. Unsubscribe anytime.

Comments 0

Advertisement

Related stories

Global Markets
As AI trade falters, Goldman Sachs says this lagging region is now positioned to outperform
MarketWatch · November 9, 2026
Global Markets
Can the AI trade catch a break? Nvidia, Anthropic and CoreWeave may have a say.
MarketWatch · November 9, 2026
Global Markets
The biggest takeaway from Berkshire Hathaway’s latest quarter isn’t the $357 billion cash or its stock buybacks
MarketWatch · November 9, 2026
Global Markets
Until sentiment in the AI trade improves, Citi tells investors it’s better to sit out the global tech trade
MarketWatch · November 9, 2026

Most read

  1. 1'Scene' BO day 2: Suriya and Naslen's film crosses Rs 80 Cr worldwideEntertainment
  2. 2NMDC Sells 2,050 Carats of Panna Diamonds, Top Bid Reaches Rs 57 LakhBusiness
  3. 3Trump offers press secretary role to White; UFC boss to meet PresidentSports
  4. 4'Scene' BO day 1: Suriya, Naslen film opens with Rs 34.25 crEntertainment
  5. 5'Ignore, See Consequences': IndiGo Flight Returns To Bengaluru After Hijack Threat Note Found In ToiletTop Stories